دواعي استعمال روفينديوم 60مجم 20 قرص

معلومات من نشرات دوائية ومراجع موثقة، مع مصدر كل معلومة. السعر الحالي: 30.5ج.م.

دواعي الاستعمال

Directory use: analgesic and anti-inflammatory for rheumatoid arthritis joints and bone pain in osteoporosis.
Relief of inflammation and pain in rheumatoid arthritis, osteoarthritis, low back pain, periarthritis of the shoulder, shoulder-arm-neck syndrome and toothache; postoperative, post-traumatic and post-extraction pain; antipyresis and analgesia in acute upper respiratory tract inflammation.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)

الآثار الجانبية

Adverse reactions in 3.03% of 13,486 patients, mainly GI symptoms (stomach discomfort, abdominal pain, nausea/vomiting, anorexia: 2.25%), oedema (0.59%), rash/urticaria (0.21%), sleepiness (0.10%).نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Clinically significant (incidence unknown): shock/anaphylactoid reactions, haemolytic anaemia, leukopenia, thrombocytopenia, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute renal failure, congestive heart failure, interstitial pneumonia, hepatic dysfunction, asthmatic attack, aseptic meningitis.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)

موانع الاستعمال

Peptic ulcer.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Severe blood disorders, severe hepatic disorders, severe renal impairment or severe cardiac failure.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
History of hypersensitivity to any ingredient.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Current or past aspirin-induced asthma.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Late stages of pregnancy.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)

تحذيرات واحتياطات

Use with caution in history of peptic ulcer, blood, hepatic or renal disorders, cardiac dysfunction, bronchial asthma, ulcerative colitis, Crohn's disease and the elderly.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Symptomatic, not causal, treatment; in chronic use perform periodic urinalysis, blood tests and liver function tests; may mask signs of infection; avoid concomitant other anti-inflammatory analgesics.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)

التداخلات الدوائية

Coumarin anticoagulants (e.g. warfarin)Anticoagulant effect may be enhanced; reduce dose as necessary.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Sulfonylureas (e.g. tolbutamide)Hypoglycaemic effect may be enhanced.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
New quinolones (e.g. enoxacin)Convulsant effect may be enhanced.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
MethotrexatePlasma methotrexate may increase.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
LithiumPlasma lithium may increase (lithium toxicity); monitor levels.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Thiazide diureticsDiuretic/antihypertensive effect may be reduced.Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)

الحمل والرضاعة

Use in women who are or may be pregnant only if the expected benefit outweighs the risk; safety not established.نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)
Avoid use in nursing women; if necessary, breastfeeding should be discontinued (excreted in rat milk).نشرة دولية لتركيبة مكافئة · Saja Pharma (Saudi Arabian Japanese Pharmaceutical Co.)

المصادر